WEST BLOOMFIELD TOWNSHIP, Mich., Sept. 5, 2023 /PRNewswire/ — Prominently featured in The Inner Circle, Susan Seman is acknowledged as a Pinnacle Platinum Professional for her contributions to the fields of General and Trauma Surgery and Wound Care.
Dr. Seman sought higher education at Michigan State University where she earned a Bachelor of Science in Psychology. She then attended the University of Osteopathic Medicine and Health Sciences in Des Moines, Iowa where she received a Doctor of Osteopathic Medicine degree. The doctor completed a general surgery residency at Botsford Hospital and a fellowship in trauma surgery at Henry Ford Hospital in Detroit.
A certified wound specialist by the American Board of Wound Management, the doctor is also board certified in general and trauma surgery and wound care by the American Osteopathic Board of Surgery (AOBS). Dr. Seman notes that the AOBS is an organization that provides board certification to qualified Doctors of Osteopathic Medicine who specialize in the use of surgery to aid in the diagnosis and treatment of disease.
According to the doctor, she uses a holistic approach, treating the whole patient, and also provides esthetic services such as Botox injections and facial and body contouring. Her responsibilities include making rounds in the hospital with medical students and residents. Based south of Orchard Lake in West Bloomfield Township in Michigan, Dr. Seman has extensive experience in the fields of wound care and cosmetics and is the Owner & Operator of The Dr. Susan Seman Solution.
Dr. Seman explained that the team at Dr. Susan Seman Solution provides patients with impactful lasting solutions for wound care, surgical needs, and comprehensive skin and body treatments are committed to inspiring patients to “live their best selves”, delivering the finest and most comprehensive care available today.
A “first choice” healthcare provider, Dr. Seman was motivated to begin offering cosmetic procedures, such as Botox, when she realized that she could treat both the inside of the patient as a surgeon and also the outside to improve wellness and confidence. What began as a simple certification in Botox treatments has allowed her services to include injectables, lasers, lights, and spa treatments.
Dr. Seman has continued to expand her practices to include osteopathic surgery at hospitals in the West Bloomfield Township area and asserts that she is highly respected among her peers. She has long-standing relationships with other local practitioners in the community and hospitals where she practices, often providing guidance in good nutrition; a healthy diet; and regular physical activity to keep patients looking and feeling healthy inside and out.
The doctor is dedicated to providing the latest advancements in her fields and is a member of many professional organizations, including fellowship status in the American College of Surgeons (FACS) and the American College of Osteopathic Surgeons (FACOS), as well as a member of the American Osteopathic Association.
Aside from her professional pursuits, Dr. Seman volunteers with D.L.I.V.E (Detroit Life is Valuable Everyday), which works to end violence in the city. The doctor would like to dedicate this honor to her mentor, John Parmly, DO, and also in memory of mentors Lee Silverman, DO, and Farouk Obeid, MD.
VERO BEACH, Fla., Sept. 5, 2023 /PRNewswire/ — Prominently featured in The Inner Circle, James C. Lasker is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology.
Dr. Lasker pursued higher education at Yale University where he earned a Bachelor of Science degree in Biology. He then attended Temple University, School of Medicine in Philadelphia receiving a Medical Doctor degree. He later attended Emory University where he finished an internship and internal medicine residency; completed a Fellowship in hematology-oncology at Baylor College of Medicine; and capped his scholarship concluding a Fellowship in bone marrow transplant at the MD Anderson Cancer Center.
Dr. Lasker explained that hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. He also noted that oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer; malignant blood diseases such as leukemia; lymphoma; and multiple myeloma; and blood disorders, such as iron-deficiency anemia; clotting abnormalities; hemophilia; and sickle-cell disease.
Realizing his calling to be a physician at a young age, Dr. Lasker explained that “When I was five, I decided I wanted to be a physician. I enjoyed putting Band-Aids on my family members and friends, as well as looking in their mouths with a tongue depressor. I chose medical oncology as a specialty because of my personal experiences with losing loved ones at an early age. I am motivated to come to work by the pure enjoyment of looking after the needs of cancer patients and their families.” He joined Alabama Oncology in 1996 as President and Managing Partner from 2011 through 2018, and currently works at their Alabaster and Princeton offices.
The doctor is board certified in internal medicine and medical oncology by the American Board of Internal Medicine (ABIM). He is also a member of the American Society of Clinical Oncology and American Society of Hematology and is president and manager of The Baptist Physician Alliance (BPA) 2009-2019, which is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world. The doctor is an active member of the Medical Association of Alabama; the Jefferson County Medical Society; and the American Society of Clinical Oncology.
Also a compassionate civic leader, Dr. Lasker has served as the President of the local soup kitchens in Alabama, raising funds for the organization. He also works with “Hand in Paw,” which provides animal or pet therapy to patients. The doctor would like to dedicate this honor to his mentors, Monty Lane, MD; Ken Walker, MD; and Jimmie Harvey, MD.
FOLSOM, N.J., Sept. 5, 2023 /PRNewswire/ — SJI today announced it has commenced a cash tender offer (the “Tender Offer”) to purchase for cash any and all of (i) the outstanding Corporate Units, each consisting of a purchase contract issued by us to purchase shares of our common stock and a 1/20, or 5%, undivided beneficial ownership interest in $1,000 principal amount of our 2021 Series B 1.65% Remarketable Junior Subordinated Notes due 2029 (the “RSNs”) (the “Corporate Units”) and (ii) the Separate RSNs (as defined in the Offer to Purchase) listed in the table below (collectively, the “Securities,” and each a “Series” of Securities) from each registered holder of the applicable Series of Securities (each, a “Holder,” and collectively, the “Holders”) subject to the terms specified in the Offer to Purchase (as defined below), including the Financing Condition (as defined in the Offer to Purchase).
Title of Security
CUSIP / ISIN
Aggregate Number of Corporate Units and Aggregate Principal Amount of Separate RSNs Outstanding
Early Tender Premium
Total Consideration(1)(2)
Corporate Units(3)
838518306 / US8385183061
3,085,100 Corporate Units
$1.50 per Corporate Unit
$69.00 per Corporate Unit
Separate RSNs
838518AB4 / US838518AB47
$173,149,000 principal amount of Separate RSNs
$30 per $1,000 principal amount of Separate RSN
$975 per $1,000 principal amount of Separate RSN
(1)
Holders whose Corporate Units are accepted for purchase pursuant to the Tender Offer will also receive (i) accrued and unpaid contract adjustment payments and (ii) accrued and unpaid interest payments, in each case from the last applicable payment date to, but excluding, the Settlement Date (as defined below). Holders whose Separate RSNs are accepted for purchase pursuant to the Tender Offer will also receive accrued and unpaid interest on their purchased RSNs from the last interest payment date for such RSNs to, but excluding, the Settlement Date. Contract adjustment payments and interest payments on the Corporate Units and interest payments on the Separate RSNs will be paid on October 1, 2023, so we expect accrued and unpaid interest payments and contract adjustment payments, as applicable, to accrue from October 1, 2023 to, but excluding, the Settlement Date.
(2)
Includes the Early Tender Premium.
(3)
Each Corporate Unit has a stated amount of $50.
Indicative timetable for the Tender Offer:
Event
Calendar Date and Time
Commencement
September 5, 2023
Early Tender Deadline
5:00 p.m., New York City time, on September 18, 2023, unless extended with respect to one or more Series of Securities.
Withdrawal Deadline
5:00 p.m., New York City time, on September 18, 2023, except in certain limited circumstances where additional withdrawal rights are required by law.
Expiration Time
5:00 p.m., New York City time, on October 3, 2023, unless extended with respect to one or more Series of Securities.
Settlement Date
Promptly after the Expiration Time. Expected to be October 5, 2023, the second business day following the Expiration Time, but subject to change.
The complete terms of the Tender Offer are set forth in the Offer to Purchase dated September 5, 2023 (as it may be amended or supplemented from time to time, the “Offer to Purchase”). Consummation of the Tender Offer is subject to a number of conditions, including the absence of certain adverse legal and market developments, as well as a Financing Condition. There can be no assurance that the Company will complete in a timely manner, or at all, the Debt Financing (as defined in the Offer to Purchase) or that the Financing Condition will be satisfied. See “Terms of the Tender Offer—Conditions to the Tender Offer” in the Offer to Purchase. Accordingly, there can be no assurance that the Tender Offer will be consummated or that any failure to consummate the Tender Offer will not have a negative effect on the market price and liquidity of the Securities. The Tender Offer is not conditioned upon any minimum amount of Series of Securities being tendered. There are no guaranteed delivery provisions applicable to the Tender Offer.
The Tender Offer will expire at 5:00 p.m., New York City time, on October 3, 2023, unless extended (such date and time, as the same may be extended, the “Expiration Time”). Holders of Securities must validly tender and not validly withdraw their Securities at or before 5:00 p.m., New York City time, on September 18, 2023, unless extended (such date and time, as the same may be extended, the “Early Tender Deadline”), to be eligible to receive the applicable Total Consideration (as defined herein) per Corporate Unit and $1,000 principal amount of the Separate RSNs tendered by such Holders that are accepted for purchase, which is equal to the applicable Tender Consideration for each Corporate Unit and $1,000 principal amount of the Separate RSNs tendered and accepted for purchase plus the applicable Early Tender Premium. The “Total Consideration” for each Corporate Unit and $1,000 principal amount of the Separate RSNs tendered and accepted for purchase pursuant to the Tender Offer will be $69.00 and $975, respectively, which Total Consideration will include the applicable Early Tender Premium. Holders whose Corporate Units are accepted for purchase pursuant to the Tender Offer will also receive (i) accrued and unpaid contract adjustment payments and (ii) accrued and unpaid interest payments, in each case from the last applicable payment date to, but excluding, the Settlement Date. Holders whose Separate RSNs are accepted for purchase pursuant to the Tender Offer will also receive accrued and unpaid interest on their purchased RSNs from the last interest payment date for such RSNs to, but excluding, the Settlement Date. Contract adjustment payments and interest payments on the Corporate Units and interest payments on the Separate RSNs will be paid on October 1, 2023, so we expect accrued and unpaid interest payments and contract adjustment payments, as applicable, to accrue from October 1, 2023 to, but excluding, the Settlement Date.
Assuming the Tender Offer is not extended and the conditions to the Tender Offer are satisfied or waived, South Jersey Industries, Inc. expects that settlement for Securities validly tendered and not validly withdrawn on or before the Early Tender Deadline, and for Securities validly tendered after the Early Tender Deadline and on or before the Expiration Time, will be on October 5, 2023 (the “Settlement Date”). Securities tendered may be validly withdrawn at any time on or before 5:00 p.m., New York City time, on September 18, 2023 (such time and date, as the same may be extended, the “Withdrawal Deadline”), but not thereafter, except in certain limited circumstances where additional withdrawal rights are required by law.
For a Holder who holds Securities through DTC to validly tender Securities pursuant to the Tender Offer, an Agent’s Message (as defined in the Offer to Purchase) and any other required documents must be received by the Tender Agent at its address set forth on the Offer to Purchase at or prior to the Expiration Time. For a Holder who holds Securities through Clearstream Banking, société anonyme or Euroclear Bank SA/NV to validly tender Securities pursuant to the Offers, such Holder must tender such Securities in accordance with the procedures of such clearing system. There is no letter of transmittal for the Offer to Purchase.
Subject to applicable law, the Tender Offer may be amended, extended, terminated or withdrawn with respect to the Securities at any time. If the Tender Offer is terminated with respect to any Series of Securities without Securities of such Series being accepted for purchase, Securities of such Series tendered pursuant to the Tender Offer will promptly be returned to the tendering Holders.
This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The Tender Offer is being made solely pursuant to terms and conditions set forth in the Offer to Purchase and only to such persons and in such jurisdictions as are permitted under applicable law.
BofA Securities is serving as the Dealer Manager in connection with the Tender Offer. Questions regarding the terms of the Tender Offer for the Corporate Units should be directed to BofA Securities at +1 (888) 803-9655 (toll free). Questions regarding the terms of the Tender Offer for the Separate RSNs should be directed to BofA Securities at +1 (888) 292-0070 (toll free), +1 (980) 387-5602 (collect) or [email protected]. Any questions or requests for assistance or additional copies of the Offer to Purchase or the documents incorporated by reference therein may be directed to D.F. King & Co., Inc., which is acting as the Tender Agent and the Information Agent for the Tender Offer, at www.dfking.com/sji and the following telephone numbers: banks and brokers at (866) 864-7964 (toll free); all others at (212) 269-5550 (all others) or email at [email protected].
About SJI
SJI, an energy infrastructure holding company based in Folsom, NJ, delivers energy services to customers through two primary subsidiaries: SJI Utilities (SJIU) and SJI Energy Enterprises (SJIEE). SJIU houses the company’s regulated natural gas utility operations, delivering safe, reliable and affordable natural gas to more than 700,000 residential, commercial and industrial customers across New Jersey via its South Jersey Gas and Elizabethtown Gas subsidiaries. SJIEE houses the company’s non-utility operations primarily focused on clean energy development and decarbonization via renewable energy production and energy management activities. Visit sjindustries.com for more information about SJI and its subsidiaries.
Forward-Looking Statements
This press release contains forward-looking statements based on current expectations and assumptions that involve risks, uncertainties and assumptions. All statements other than statements of historical fact, including statements regarding guidance, industry prospects or future results of operations or financial position, expected sources of incremental margin, strategy, financing needs, future capital expenditures and the outcome or effect of ongoing litigation, are forward-looking. Forward looking statements can also generally be identified by words such as “believe,” “expect,” “intend,” “seek,” “strategy,” “would,” “could,” “should,” “may,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the beliefs and assumptions of management at the time that these statements were prepared and are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, general economic conditions on an international, national, state and local level; weather conditions in SJI’s marketing areas; changes in commodity costs; changes in the availability of natural gas; “non-routine” or “extraordinary” disruptions in SJI’s distribution system; cybersecurity incidents and related disruptions; regulatory, legislative and court decisions; competition; the availability and cost of capital; costs and effects of legal proceedings and environmental liabilities; the failure of customers, suppliers or business partners to fulfill their contractual obligations; changes in business strategies; acquisition-related liabilities; the diversion of management time on acquisition-related issues; and public health crises and epidemics or pandemics, such as the COVID-19 pandemic. These risks and uncertainties, as well as other risks and uncertainties that could cause our actual results to differ materially from those expressed in the forward-looking statements, are described in greater detail in (i) in “Terms of the Tender Offer—Certain Significant Consequences to Holders” in the Offer to Purchase including our ability to successfully complete the Debt Financing and (ii) “Risk Factors” in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2021. These cautionary statements should not be construed by you to be exhaustive and they are made only as of the date of this press release. While the Company believes these forward-looking statements to be reasonable, there can be no assurance that they will approximate actual experience or that the expectations derived from them will be realized. Further, the Company undertakes no obligation to update or revise any of its forward-looking statements whether as a result of new information, future events or otherwise.
NEW YORK, Sept. 5, 2023 /PRNewswire/ — The pet food market size is expected to grow by USD 35.75 billionfrom 2022 to 2027, according to Technavio. In addition, the growth momentum of the market will progress at a CAGR of about 5.71% during the forecast period. Growing demand for organic pet food is notably driving the pet food market. However, factors such as Increasing instances of pet allergies among pet owners may impede market growth. Technavio provides a comprehensive report summary describing the market size and forecast along with research methodology. The sample report is available in PDF format
Technavio has announced its latest market research report titled Global Pet Food Market 2023-2027
The growing demand for organic pet food notably drives the market growth. Organic pet food adheres to USDA regulations, ensuring it meets the standards for the organic label. As consumers become more conscious of pet food ingredients, a trend paralleling their concerns for human food, the popularity of organic and natural pet food is rising. The global organic pet food market is witnessing substantial growth due to heightened pet owner focus on their pets’ health and well-being, coupled with the emerging trend of pet humanization. With many considering their pets as part of their families, the demand for organic and natural pet food has surged. Presently, organic food options for small reptiles are limited compared to small mammals, given the lower adoption rate of small reptiles. However, as the adoption of smaller reptiles grows in the coming years, the popularity of organic food in this category is likely to increase. Consequently, the rising demand for organic pet food is expected to drive the expansion of the global pet food market throughout the forecast period.
Key Segment Analysis The market is segmented by product (Dry food, Wet food, and Snacks and treats), type (Dog food, Cat food, and Others), and geography (North America, Europe, APAC, South America, and Middle East and Africa).
The market share growth by the dry foodsegment will be significant during the forecast period. Dry pet food offers convenient storage and transportation, providing cost savings and benefits to customers. With its minimal storage risk, dry pet food maintains its quality over time. Compared to wet pet food’s high water content of 75%, dry pet food contains only 10% water, contributing to better oral hygiene for pets. Additionally, dry pet food can be used in food puzzle toys, promoting controlled food intake. The growing number of pet owners globally, especially in emerging markets like India and Malaysia, is driving the growth of the dry food segment in the global pet food market during the forecast period.
To know additional highlights and key points on various market segments and their impact in coming years, View PDF Sample Report.
Geographical Market Analysis
· North America is estimated to contribute 35% to the growth of the global market during the forecast period.
Company Insights The pet food market is fragmented, and the companies are deploying organic and inorganic growth strategies to compete in the market. The report analyzes the market’s competitive landscape and offers information on several market companies, including Agrolimen SA, Archer Daniels Midland Co., C and D Foods Ltd., Colgate Palmolive Co., General Mills Inc., Global Pet Foods, Hartz Mountain Corp., Himalaya Global Holdings Ltd., Mars Inc., Merrick Pet Care Inc., Nestle SA, Nippon Pet Food Co. Ltd, NutriSource Pet Foods, Premier Petfoods Company Pty Ltd, Schell and Kampeter Inc., Sunshine Mills Inc., The J.M Smucker Co., Tiernahrung Deuerer GmbH, Wellness Pet Co. Inc., and Unicharm Corp.
Challenge
The usage of artificial colors or flavor enhancers, antibiotics, herbicides, pesticides, and chemical preservatives in pet food offerings is a major challenge hindering market growth. Food additives are utilized by the food industry to enhance the flavor, appearance, and preservation of products. One common additive, MSG, acts as a flavor enhancer in pet foods, although it lacks inherent taste. MSG tricks the brain into perceiving enhanced flavor by stimulating dopamine production, generating a brief sense of well-being. However, prolonged consumption can disrupt brain function and responsiveness. This class of compounds, excitotoxins, can lead to overstimulation of the brain and induce issues like obesity, neuroendocrine disturbances, and behavioral changes. Moreover, MSG exhibits toxicity to various organs, including the liver, brain, thymus, and kidneys. Presently, pet owners are increasingly conscious of the benefits of natural food for their pets’ well-being. They avoid pet foods containing additives, preservatives, and flavor enhancers, negatively influencing the growth of the global pet food market during the forecast period.
View PDF Sample Report to find additional highlights on the growth strategies adopted by companies and their product offerings.
Related Reports:
The pet dietary supplements market is estimated to grow at a CAGR of 5.9% between 2022 and 2027. The market size is forecast to increase by USD 914.46 million.
The pet daycare and lodging market size is estimated to grow at a CAGR of 6.98% between 2022 and 2027. The market size is forecast to increase by USD 10.18 billion.
Pet Food Market Scope
Report Coverage
Details
Base year
2022
Historic period
2017-2021
Forecast period
2023-2027
Growth momentum & CAGR
Accelerate at a CAGR of 5.71%
Market growth 2023-2027
USD 35.75 billion
Market structure
Fragmented
YoY growth 2022-2023 (%)
5.47
Regional analysis
North America, Europe, APAC, South America, and Middle East and Africa
Performing market contribution
North America at 35%
Key countries
US, Japan, UK, France, and Brazil
Competitive landscape
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
Agrolimen SA, Archer Daniels Midland Co., C and D Foods Ltd., Colgate Palmolive Co., General Mills Inc., Global Pet Foods, Hartz Mountain Corp., Himalaya Global Holdings Ltd., Mars Inc., Merrick Pet Care Inc., Nestle SA, Nippon Pet Food Co. Ltd, NutriSource Pet Foods, Premier Petfoods Company Pty Ltd, Schell and Kampeter Inc., Sunshine Mills Inc., The J.M Smucker Co., Tiernahrung Deuerer GmbH, Wellness Pet Co. Inc., and Unicharm Corp.
Market dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Product
Market Segmentation by Type
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
SÃO PAULO, 5 de septiembre de 2023 /PRNewswire/ — Antaisolar, el proveedor líder de toda la cadena de la industria en sistemas de montaje fotovoltaico, presentó sus innovadoras soluciones solares, incluyendo los avanzados sistemas de seguimiento 1P TAI-Simple, productos de montaje distribuido y sistema de montaje en suelo en Intersolar Sudamérica 2023. Gracias al excelente diseño de su stand, sus eficientes soluciones de sistemas y sus servicios profesionales, Antaisolar atrajo a numerosos promotores, mayoristas, EPC y otras empresas del sector.
TAI-Simple, el innovador sistema rastreador 1P de Antaisolar (PRNewsfoto/Antaisolar)
Rastreador 1P TAI-Simple: En busca de la luz en Sudamérica
Situado en una zona de baja latitud, Brasil es rico en recursos de luz diurna, que tienen buenas condiciones naturales y un gran potencial para desarrollar la energía solar, especialmente en proyectos fotovoltaicos a gran escala. TAI-Simple, el innovador sistema de seguimiento 1P de Antaisolar, combina las ventajas de estabilidad, seguridad y alta eficiencia. En aplicaciones prácticas, puede satisfacer los requisitos de proyectos fotovoltaicos a gran escala en Sudamérica, con un avanzado diseño de accionamiento de un solo punto que soporta velocidades de viento extremas y se ajusta a todo tipo de situaciones de vientos fuertes. También se adapta a módulos de gran tamaño o bifaciales, logrando un mayor rango de seguimiento, lo que puede aumentar los beneficios de generación y reducir los costos de operación.
Solución distribuida para todos los escenarios: Techos más potentes
Con el apoyo normativo, la energía fotovoltaica distribuida en Brasil se está desarrollando rápidamente. Para responder a la enorme demanda del mercado distribuido, Antaisolar aportó soluciones más adaptables que satisfacen las necesidades de todos los escenarios, como tejados planos, tejados de tejas, tejados metálicos, etc. Estos productos han sido sometidos a múltiples pruebas y certificaciones internacionales, garantizando su estabilidad, accesibilidad y sostenibilidad. Pueden ayudar a los clientes a simplificar la instalación, reducir los costos de mano de obra, mejorar la estética y aumentar la eficiencia en la generación de energía.
Antaisolar pone un énfasis significativo en el mercado sudamericano, dedicando esfuerzos para desarrollar sistemas de servicio localizados. En 2018, se estableció una oficina local en Brasil para garantizar respuestas rápidas y una entrega eficiente. Recientemente, se aseguró un importante proyecto de 187MW en Brasil, marcando la continua expansión en toda América Latina. Con la misión de “Crear un mundo verde”, Antaisolar está impulsada por la innovación, la profesionalidad y el firme compromiso de satisfacer las necesidades de los clientes. Contribuye activamente al desarrollo de energías renovables en Sudamérica y trabaja incansablemente para promover la causa de la construcción de una sociedad con bajas emisiones de carbono.
BOCA RATON, Fla., Sept. 5, 2023 /PRNewswire/ — Relaxium®, a trusted name in sleep solutions, is excited to announce its collaboration with industry leaders to revolutionize the ordering process and prioritize consumer rights. With a commitment to transparency and customer satisfaction, Relaxium® is working tirelessly to bring an enhanced ordering experience to its valued customers.
As part of its ongoing dedication to providing the best possible service, Relaxium® is securing services of industry leaders to implement significant improvements to its ordering process. The focus is on simplifying the online sign-up process for customers who wish to try our free trial. By working with renowned experts, Relaxium® is developing an ordering system that combines ease of use with clear disclosures, ensuring customers have all the necessary information at their fingertips.
One of the key enhancements is the introduction of easy-to-read disclosures, which will provide customers with a comprehensive understanding of our products and subscription terms. We believe that transparency is crucial in building trust with our customers, and our collaboration with industry leaders allows us to deliver a simplified and transparent ordering experience.
In addition to improved disclosures, Relaxium® is committed to making the ordering process for the free trial as simple as possible. Our collaboration with industry leaders enables us to streamline the process, ensuring that customers can easily navigate through the steps to enjoy the benefits of Relaxium® Sleep. We understand the importance of a user-friendly interface, and our goal is to provide a hassle-free experience from start to finish.
To further enhance the customer experience, Relaxium® has already implemented its renowned customer success service hotline and help desk accessible 24/7 at help.relaxium.com. Our dedicated team of professionals is ready to provide assistance and address any questions or concerns our customers may have.
At Relaxium®, we believe that consumer rights are paramount. That’s why our collaboration with industry leaders is focused on providing a cancellation mechanism that is clear and straightforward, ensuring that customers have full control over their subscriptions.
“We are thrilled to work with industry leaders who share our vision of prioritizing customer satisfaction and consumer rights,” said Timea Ciliberti, Founder and CEO at Relaxium®. “By combining our expertise with their knowledge, we are confident that the enhanced ordering experience will exceed our customers’ expectations.”
For more information about Relaxium® and its commitment to customer satisfaction, please visit our website at https://help.relaxium.com/ or contact our customer support team via the toll-free number: 1-888-353-1205.
About Relaxium®:
Relaxium® is a trusted provider of premium sleep solutions, dedicated to helping individuals achieve restful and rejuvenating sleep. With a focus on transparency and customer satisfaction, Relaxium® offers effective and non-habit-forming sleep products that prioritize the well-being of its customers.
